by mdehxaba | Mar 19, 2026 | News
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own immune arsenal to fight cancer. In the trial, which is still in...
by mdehxaba | Mar 19, 2026 | News
The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...
by mdehxaba | Mar 5, 2026 | Publications
The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...
